IP Library › Granted Patent US 12,653,855
Granted Patent B2
US 12,653,855 · App. 18/320,001 · Granted Jun 16, 2026

Optimizing volatile entourages in dry flowering plant mixtures

Inventor: Michael Dane Backes (Fallbrook, CA)
Assignee: Perfect Herbal Blends, Inc.
A61K36/3482A24D1/18A61K31/01A61K31/015A61K31/045A61K31/336A61K31/352A61K36/185A61K36/3486A61K2236/15A61K2236/17A61K2236/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,855
App. No.
18/320,001
Granted
Jun 16, 2026
Kind
B2
Abstract

Novel fragrant and flavorful Cannabis plant products with defined chemistry customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

Claims (25)

1 . A fragrant and flavorful Cannabis plant product with a formulation comprising a mixture of (a) dried and chopped plant material from one or more Cannabis plant types, and (b) an Entourage of Interest (EOI) extract from one or more Cannabis plant types comprising one or more lipids, and one or more fragrant and flavorful compounds, wherein the one or more fragrant and flavorful compounds include one or more terpenes, and wherein at least 50% of the one or more terpenes are stably maintained in the Cannabis plant product when the plant product is stored at room temperature for 30 days or longer.

2 . The fragrant and flavorful cannabis plant product of claim 1 , wherein the EOI extract includes THCa and the EOI extract that has been treated to reduce the amount of THCa resulting in a THCa-reduced EOI extract.

3 . The fragrant and flavorful cannabis plant product of claim 1 , wherein the EOI extract, the dried and chopped plant material substrate or the cannabis plant product is supplemented with THCa or THC.

4 . The fragrant and flavorful cannabis plant product of claim 3 , wherein the cannabis plant product is supplemented with crystalline THCa and/or a cannabinoid isolate or distillate.

5 . The fragrant and flavorful cannabis plant product of claim 1 , wherein the cannabis plant type is a marijuana cultivar selected from the group consisting of Cannabis sativa subsp. sativa var. sativa, Cannabis sativa subsp. sativa var. spontanea, Cannabis sativa subsp. indica var. indica, Cannabis sativa subsp. indica var. afghanica, Cannabis sativa subsp. indica var. himalayensis , and Cannabis sativa subsp. indica var. asperrima.

6 . The fragrant and flavorful cannabis plant product of claim 1 , wherein at least 70%, of the one or more terpenes in the cannabis plant product are stably maintained for at least 30 days when stored at room temperature.

7 . The fragrant and flavorful cannabis plant product of claim 1 , wherein the one or more terpenes comprise monoterpenes, diterpenes and/or sesquiterpenes.

8 . The fragrant and flavorful cannabis plant product of claim 1 , wherein the cannabis plant product is supplemented with fragrant and flavorful compounds.

9 . The fragrant and flavorful cannabis plant product of claim 1 , wherein the total cannabinoid content in the cannabis plant product is from about 0.1% to 45% cannabinoids.

10 . The fragrant and flavorful cannabis plant product of claim 7 , wherein the one or more terpenes in the cannabis plant product include one or more of β-caryophyllene, β-myrcene, limonene, linalool, α-humulene, β-pinene, α-pinene, α-bisabolol, α-terpinene, β-ocimene, camphene, caryophyllene oxide, cis-nerolidol, γ-3-carene, eucalyptol, γ-terpinene, geraniol, ocimene, (−)-guaiol, (−)-isopulegol, p-cymene, terpinolene, trans-nerolidol, gerol, geranyl acetate, α-terpineol, α-phellanderene, sabinene, thymol, cedrene, cedrol, fenchol, valencene, α-thujene, and cymene.

11 . The fragrant and flavorful cannabis plant product of claim 10 , wherein the total monoterpene content in the cannabis plant product is from 1% to 10%.

12 . The fragrant and flavorful cannabis plant product of claim 7 , wherein the total sesquiterpene content in the cannabis plant product is less than 2%.

13 . The fragrant and flavorful cannabis plant product of claim 1 , further comprising from about 0.2 to 4.0% micro pulverized cannabis leaf.

14 . The fragrant and flavorful cannabis plant product of claim 1 , wherein the dried and chopped plant material further comprises one or more of hops, basil, mimosa, passion flower, corn silk, rose petals, lotus leaf, licorice root, jasmine, ginseng, red clover flowers, bergamot, lemon, lime, sweet orange, tangerine, mandarin, cinnamon bark, citronella, lemongrass, petitgrain, palmarosa, patchouli leaves, geranium, lavender, rosemary, spike lavender, ginger, vetiver, jasmine, neroli (orange blossom), and ylang-ylang.

15 . The fragrant and flavorful cannabis plant product of claim 1 , packaged as a pre-roll or cigarette form.

16 . The fragrant and flavorful cannabis plant product of claim 1 , wherein the cannabis plant product is supplemented with one or more powdered or liquid cannabinoids.

17 . The fragrant and flavorful cannabis plant product of claim 8 , wherein the cannabis plant product is supplemented with one or more powdered or liquid cannabinoids.

18 . A fragrant and flavorful Cannabis plant product with a formulation having defined chemistry comprising a mixture of (a) dried and chopped plant material from a marijuana cultivar, and (b) an Entourage of Interest (EOI) extract comprising fragrant and flavorful compounds, wherein the fragrant and flavorful compounds are stably maintained in the Cannabis plant product when the plant product is stored at room temperature for 30 days or longer, wherein the marijuana cultivar is Cannabis sativa subsp. indica var. indica , and wherein the fragrant and flavorful compounds include limonene and myrcene, wherein at least 50% of the limonene and myrcene in the cannabis plant product are stably maintained for at least 30 days when stored at room temperature.

19 . The fragrant and flavorful cannabis plant product of claim 18 , wherein the EOI extract includes THCa and the EOI extract that has been treated to reduce the amount of THCa resulting in a THCa-reduced EOI extract.

20 . The fragrant and flavorful cannabis plant product of claim 18 , wherein the EOI extract, the dried and chopped plant material substrate or the cannabis plant product is supplemented with THCa or THC.

21 . The fragrant and flavorful cannabis plant product of claim 20 , wherein the cannabis plant product is supplemented with crystalline THCa and/or a cannabinoid isolate or distillate.

22 . The fragrant and flavorful cannabis plant product of claim 18 , packaged as a pre-roll or cigarette form.

23 . The fragrant and flavorful cannabis plant product of claim 1 , wherein at least 90% of the one or more terpenes in the cannabis plant product are stably maintained for at least 30 days when stored at room temperature.

24 . The fragrant and flavorful cannabis plant product of claim 18 , wherein at least 70% of the limonene and myrcene in the cannabis plant product are stably maintained for at least 30 days when stored at room temperature.

25 . The fragrant and flavorful cannabis plant product of claim 18 , wherein at least 90% of the limonene and myrcene in the cannabis plant product are stably maintained for at least 30 days when stored at room temperature.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2024
From: BACKES, MICHAEL DANE
To: PERFECT HERBAL BLENDS, INC.
Reel/Frame 069042/0954 →
Continuity (5)
Continuation In Part 17560057 · Dec 22, 2021
Continuation 17012526 · Sep 4, 2020
Provisional Application 62992154 · Mar 20, 2020
Provisional Application 62896775 · Sep 6, 2019
Related Publication 20230285485A1 · Sep 14, 2023
References Cited (77)
US 7363929B2 · Fagg et al. · 2008 [cited by applicant]
US 9095554B2 · Lewis et al. · 2015 [cited by applicant]
US 9370164B2 · Lewis et al. · 2016 [cited by applicant]
US 9642317B2 · Lewis et al. · 2017 [cited by applicant]
US 9649349B1 · Tucker et al. · 2017 [cited by applicant]
US 9730911B2 · Verzura et al. · 2017 [cited by applicant]
US 9919241B1 · Auerbach et al. · 2018 [cited by applicant]
US 10092852B2 · Tucker · 2018 [cited by applicant]
US 10238706B1 · Nahtigal · 2019 [cited by applicant]
US 10315129B1 · Auerbach et al. · 2019 [cited by applicant]
US 10323014B2 · Robertson et al. · 2019 [cited by applicant]
US 20060090769A1 · Woodson et al. · 2006 [cited by applicant]
US 20100116281A1 · Marshall et al. · 2010 [cited by applicant]
US 20160106705A1 · Verzura et al. · 2016 [cited by applicant]
US 20160366926A1 · Uren · 2016 [cited by applicant]
US 20170008870A1 · Dibble et al. · 2017 [cited by applicant]
US 20170266245A1 · Scialdone · 2017 [cited by applicant]
US 20170273349A1 · Moore · 2017 [cited by applicant]
US 20170333503A1 · Ayres · 2017 [cited by applicant]
US 20170360861A1 · Humphreys et al. · 2017 [cited by applicant]
US 20170367408A1 · Pang et al. · 2017 [cited by applicant]
US 20180143212A1 · Giese et al. · 2018 [cited by applicant]
US 20180169035A1 · Eyal · 2018 [cited by applicant]
US 20180280459A1 · Eyal · 2018 [cited by applicant]
US 20180284145A1 · Giese et al. · 2018 [cited by applicant]
US 20180289062A1 · Lopez · 2018 [cited by applicant]
US 20180296616A1 · Rivas · 2018 [cited by applicant]
US 20180296617A1 · Rivas · 2018 [cited by applicant]
US 20180343901A1 · Leo et al. · 2018 [cited by applicant]
US 20180344785A1 · Robertson · 2018 [cited by applicant]
US 20180369191A1 · Muscarella et al. · 2018 [cited by applicant]
US 20190022158A1 · Greenbaum et al. · 2019 [cited by applicant]
US 20190105859A1 · Dunn · 2019 [cited by applicant]
US 20190192422A1 · Shibaz et al. · 2019 [cited by applicant]
WO WO2014159688A1 · 2014 [cited by applicant]
WO WO2017193072A1 · 2017 [cited by applicant]
WO WO2018112479A1 · 2018 [cited by applicant]
WO WO2018195562A1 · 2018 [cited by applicant]
WO WO2018226899A1 · 2018 [cited by applicant]
WO WO2019034936A2 · 2019 [cited by applicant]
WO WO2019113574A1 · 2019 [cited by applicant]
WO WO2019130201A1 · 2019 [cited by applicant]
WO WO2019133952A2 · 2019 [cited by applicant]
Wianowska et al., “Transformations of Tetrahydrocannabionl, Tetrahydrocannabinolic Acid and Cannabinol during Their Extraction from [cited by applicant]
McPartland et al., “A Classification of endangered high-THC cannabis ( [cited by applicant]
McPartland et al., Supplementary materials to “A Classification of endangered high-THC cannabis ( [cited by applicant]
Bottger, Angelika et al., “Lessons on Caffeine, Cannabis & Co, Plant-derived Drugs and their Interaction with Human Receptor,” Learning Materials in Biosciences, Springer, 2018. [cited by applicant]
Marina Santiago, et al., “Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of D9-THC at Human CB1 and CB2 Receptors.” Cannabis and Cannabinoid Research. vol. 4, … [cited by applicant]
Morgan, Celia J. A. et al., “Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function,” Translational Psychiatry 8:181, 2018. [cited by applicant]
Wise, Kimber et al., “Inhalation Absorption Prediction (IAP) Model for Predicting Medicinal Cannabis Phytochemical Pharmacokinetics”, Pharmacogn. Commn. 2019; 9(3): 85-90, Jun. 2019. [cited by applicant]
Cunningham, Christopher W., “Plant-Based Modulators of Endocannabinoid Signaling”, J. Nat. Prod., 82, 3, 636-646, 2019. [cited by applicant]
McPartland, John M. et al., “Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System” PLoS One. 9(3):e89566, pub. Mar. 12, 2014. [cited by applicant]
Mudge EM, et al.“The Terroir of Cannabis: Terpene Metabolomics as a Tool to Understand Cannabis sativa Selections”, Planta Med. 85(9-10):781-796, Apr. 30, 2019. [cited by applicant]
Chandra, S, et al. “ [cited by applicant]
Small, E., “Cannabis A Complete Guide,” Agriculture and Agri-Food Ottawa, Ontario, Canada, CRC Press Taylor & Francis Group, pub. Oct. 14, 2016. [cited by applicant]
Russo, E. (2019) “The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No Strain,” No Gain, Front Plant Sci. Jan 9;9:1969, 2019. [cited by applicant]
Labate, Beatriz Caiuby, et al. Eds., “Plant Medicines, Healing and Psychedelic Science Cultural Perspective,” Springer International Publishing AG, 2018. [cited by applicant]
Hillig et al., “A Chemotaxonomic Analysis of Cannabinoid Variation in Cannabis (Cannabaceae)” American Journal of Botany 91(6): 966-975, 2004. [cited by applicant]
de Meijer et al., “The inheritance of chemical phenotype in [cited by applicant]
de Meijer et al., “The inheritance of chemical phenotype in [cited by applicant]
Mandolino et al.,“Potential of marker-assisted selection in hemp genetic improvement” Euphytica 140, pp. 107-120, Jan. 2004. [cited by applicant]
Staginnus, C. et al., “A PCR marker linked to a THCA synthase polymorphism is a reliable tool to discriminate potentially THC-rich plants of [cited by applicant]
de Meijer et al., “The inheritance of chemical phenotype in Cannabis sativa L. (Iv): cannabinoid- free plants” Euphytica, 168: 95-112, pub. Jan. 31, 2009. [cited by applicant]
de Meijer et al., “The inheritance of chemical phenotype in [cited by applicant]
Lewis, M. et al., “Pharmacological Foundations of Cannabis Chemovars,” Planta Medica 84(4) 225-233, published Nov. 21, 2017. [cited by applicant]
Fischedick, Justin T., (2017) “Identification of Terpenoid Chemotypes Among High O-trans-D9—Tetrahydrocannabinol-Producing [cited by applicant]
https://www.alchimiaweb.com/blogen/make-ice-water-hash/, Alchimiaweb S.L. Grow Shop, Girona, Spain, Alchimiaweb S.L. ⋅ CIF: B-17664368, 2001-2021. [cited by applicant]
https://www.alchimiaweb.com/blogen/make-thca-crystals-solventless-sauce/, Alchimiaweb S.L. Grow Shop, Girona, Spain, Alchimiaweb S.L. ⋅ CIF: B-17664368,2001-2021. [cited by applicant]
Stith, S. et al.,The Association between Cannabis Product Characteristics and Symptom Relief Sci Rep (2019) 9:2712, published Feb. 25, 2019. [cited by applicant]
Nuutinen T. “Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus” Eur J Med Chem. 157:198-228, Jul. 31, 2018. [cited by applicant]
Pertwee, Roger, “Handbook of Cannabis,” Oxford University Press, Oxford, United Kingdom, 2014. [cited by applicant]
Russo et al., “Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads,” Adv Pharmacol. 2017:80:67-134, Jun. 5, 2017. [cited by applicant]
International Search Report for International application PCT/US2020/049508, dated Mar. 24, 2021 from the International Searching Authority. [cited by applicant]
Written Opinion for International application PCT/US2020/049508, dated Mar. 24, 2021 from the International Searching Authority. [cited by applicant]
U.S. Appl. No. 17/560,057, filed Dec. 22, 2021. [cited by applicant]
U.S. Appl. No. 17/012,526, filed Sep. 4, 2020. [cited by applicant]
Backes, “Cannabis Pharmacy: The Practical Guide to Medical Marijuana,” Black Dog & Leventhal Publishers, Sep. 2014, revised Dec. 2017. [cited by applicant]